PainReform

Company Overview

Snapshot

Founded in December 2007, PainReform operates with 1–10 employees and has raised a total of $46.3M across 5 funding rounds from 4 investors. The company went public on NASDAQ in September 2020.

Business overview

PainReform is a clinical-stage specialty pharmaceutical company that develops reformulated established therapeutics. The company's core technology is a proprietary drug-delivery system designed to provide extended post-surgical pain relief, reduce the need for repeated dose administration, and decrease reliance on opiates. PainReform leverages the FDA's 505(b)(2) regulatory pathway to accelerate drug development by incorporating generic drugs with proven safety and efficacy into its extended-release system. The company's lead product, PRF-110, targets the post-operative pain relief market and is based on the local anesthetic ropivacaine. PainReform operates within the Health Tech & Life Sciences sector, specifically focusing on Pharmaceuticals and Drug Delivery, serving patients and healthcare providers in markets including North America, Europe, Israel, and Asia.

Strategic signal

In May 2026, PRF Technologies, an entity associated with PainReform, announced that its PRF-110 demonstrated sustained 72-hour analgesic activity in a head-to-head preclinical study, comparable to an approved commercial benchmark. This preclinical validation of PRF-110's extended pain relief capabilities signals potential for a competitive advantage in the post-operative pain management market, suggesting a strong scientific foundation for its ongoing clinical development and future commercialization prospects.

Company Intelligence Q&A

What was a significant recent development for PRF-110?

In May 2026, PRF Technologies announced that PRF-110 demonstrated sustained 72-hour analgesic activity comparable to an approved commercial benchmark in a head-to-head preclinical study.

What was a key strategic acquisition for PainReform?

In March 2025, PainReform completed the strategic acquisition of DeepSolar, aiming to unlock new growth opportunities in AI-driven solar analytics.

What was the outcome of PainReform's public offering in April 2024?

In April 2024, PainReform announced the pricing of a $4 million public offering on NASDAQ.

What was the most recent business update provided by PainReform?

In October 2025, PainReform provided a business update for the six months ended June 30, 2025.

What was a recent development regarding PainReform's DeepSolar initiative?

In May 2025, PainReform launched a strategic AI pilot with Econergy using its proprietary DeepSolar™ platform to optimize one of Romania’s largest solar projects.